Potential of CRISPR-Cas system in the diagnosis and therapy of COVID-19 infection

Crisper protein structures are short palindromic replications of regular clusters, and their associated proteins (CRISPR / Cas) were first identified in E. coli in 1987, which identified prokaryotic cells against any invasive, harmful pathogens and plasmids were protected. Several genome editing approaches have been used based on these mechanisms. The most recent of these is known as CRISPR / Cas, which has attracted much attention in the scientific community, especially for the diagnosis and treatment of disease, because it is faster, cheaper, and more accurate than other genome editing methods. The unprecedented expansion of COVID-19 around the world has created new challenges. Evidence of gene mutations in specific patients and the use of CRISPR / Cas can help to predict the optimal treatment plan for patients. In addition, CRISPR / Cas provides a tool for manipulating non-coding regions, thus accelerating the study of these poorly characterized genome regions and playing a vital role in the development of entire genome libraries.
Objective: To study the mechanisms of CRISPR techniques as a tool for studying natural mutations and genomic manipulations, and to evaluate how CRISPR / Cas works in the treatment of COVID-19